Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2025-09-17 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience AB announces final outcome of exercise of warrants series TO 13
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the final outcome of a warrant exercise (TO 13) for Alligator Bioscience AB. It details the number of shares issued, the gross proceeds received, and the resulting change in share capital and total shares outstanding. This falls under the category of 'Share Issue/Capital Change' (SHA) as it describes the issuance of new shares resulting from the exercise of financial instruments.
2025-09-17 English
Alligator Bioscience AB meddelar slutligt utfall för nyttjandet av teckningsoptioner serie TO 13
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Alligator Bioscience AB announcing the final outcome of the exercise of warrants (serie TO 13). It details the number of warrants exercised, the resulting number of new shares issued, the increase in share capital, and the gross proceeds received. This type of announcement regarding the issuance of new shares following the exercise of warrants falls under the category of 'Share Issue/Capital Change'.
2025-09-17 Swedish
Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 13
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the preliminary outcome of a warrant exercise (series TO 13) for Alligator Bioscience AB. It details the number of warrants exercised, the number of new shares to be issued, and the capital raised. This falls under the category of share issues and capital changes resulting from the exercise of financial instruments.
2025-09-16 English
Alligator Bioscience AB meddelar preliminärt utfall för nyttjandet av teckningsoptioner serie TO 13
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Alligator Bioscience AB announcing the preliminary outcome of the exercise of warrants (serie TO 13). It details the number of warrants exercised, the number of new shares issued, and the capital raised. This falls under the category of capital structure changes and share issuance resulting from warrant exercises. While it mentions a final outcome will be published later, this document itself is the primary announcement of the event, fitting the 'Share Issue/Capital Change' category.
2025-09-16 Swedish
Sista dag för handel med teckningsoptioner serie TO 13 i Alligator Bioscience är den 11 september 2025
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Alligator Bioscience announcing the final trading day for a specific series of warrants (TO 13) and providing details on the exercise period for these warrants to be converted into shares. This relates to capital structure and share issuance mechanics. While it mentions the company's capital, it is specifically an announcement regarding the timeline and mechanics of a warrant exercise, which falls under the category of share issues and capital changes.
2025-09-11 Swedish
Last day of trading in warrants series TO 13 in Alligator Bioscience is 11 September 2025
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the last day of trading for warrants (series TO 13) and providing details on the exercise period, subscription price, and potential share capital dilution. This relates to capital structure changes and the issuance of new shares upon warrant exercise. According to the filing definitions, announcements regarding new share issues or capital changes are classified as 'SHA'.
2025-09-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.